VanEck Associates’s Nektar Therapeutics NKTR Stock Holding History

VanEck Associates’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-9,300	Closed	-$4.96M	–	854
2019 Q2	$4.96M	Sell	9,300 -5,809	-38%	-$2.91M	0.02%	343
2019 Q1	$7.62M	Buy	15,109 +650	+4%	+$385K	0.04%	259
2018 Q4	$7.13M	Sell	14,459 -389	-3%	-$235K	0.04%	255
2018 Q3	$13.6M	Buy	14,848 +2,404	+19%	+$2.05M	0.07%	217
2018 Q2	$9.12M	Buy	12,444 +972	+8%	+$1.12M	0.04%	237
2018 Q1	$18.3M	Buy	+11,472	New	+$14.8M	0.09%	182
2017 Q1	–	Sell	-110	Closed	-$20K	–	902
2016 Q4	$20K	Buy	110 +54	+96%	+$11K	﹤0.01%	865
2016 Q3	$14K	Sell	56 -31	-36%	-$7.98K	﹤0.01%	852
2016 Q2	$19K	Buy	87 +8	+10%	+$1.79K	﹤0.01%	830
2016 Q1	$16K	Buy	+79	New	+$15.2K	﹤0.01%	808

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VanEck Associates's NKTR Position: Q3 2019 in Review

VanEck Associates sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 9,300 shares — an estimated $4.96M sold.

VanEck Associates first reported a position in NKTR in Q1 2016 and held it in 10 quarters. The position peaked at $18.3M in Q1 2018. 287 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

VanEck Associates reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
VanEck Associates sold 9,300 Nektar Therapeutics shares in Q3 2019, an estimated $4.96M.
VanEck Associates first reported a position in Nektar Therapeutics in Q1 2016 and held it in 10 quarters.
VanEck Associates's Nektar Therapeutics position peaked at $18.3M in Q1 2018.
287 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on VanEck Associates's 13F filing for Q3 2019, filed 8 Nov 2019.